Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Practice Guideline
. 2018 Apr;103(4):574-581.
doi: 10.1002/cpt.1004. Epub 2018 Feb 2.

Clinical Pharmacogenetics Implementation Consortium Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update

Affiliations
Free PMC article
Practice Guideline

Clinical Pharmacogenetics Implementation Consortium Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update

Elizabeth J Phillips et al. Clin Pharmacol Ther. .
Free PMC article

Abstract

The variant allele HLA-B*15:02 is strongly associated with greater risk of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) in patients treated with carbamazepine or oxcarbazepine. The variant allele HLA-A*31:01 is associated with greater risk of maculopapular exanthema, drug reaction with eosinophilia and systemic symptoms, and SJS/TEN in patients treated with carbamazepine. We summarize evidence from the published literature supporting these associations and provide recommendations for carbamazepine and oxcarbazepine use based on HLA genotypes.

Conflict of interest statement

Conflicts of Interest:

The authors declared no competing interests for this work.

Similar articles

See all similar articles

Cited by 18 articles

See all "Cited by" articles

Publication types

MeSH terms

Feedback